Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events - Schedule of Pro Forma Table Shows the Number of Issued and Outstanding Shares (Details)

v3.20.2
Subsequent Events - Schedule of Pro Forma Table Shows the Number of Issued and Outstanding Shares (Details) - Subsequent Event [Member] - Underwritten Public Offering [Member]
Oct. 06, 2020
shares
Actual shares issued and outstanding 5,765,566
Shares sold in the underwritten common stock offering which closed on October 6, 2020 4,800,000
Shares to be issued as a result of triggering the anti-dilution provision of previously issued shares of common stock 1,156,480
Shares to be issued to Yuhan Corporation, Elion Oncology, Inc. and Aposense Ltd. in connection with the respective license agreements. 1,700,000
Restricted stock awards that vested on the completion of our underwritten offering and up-list to the Nasdaq Capital Market on October 6, 2020 214,078
Pro forma shares issued and outstanding 13,835,661
DKBK Enterprises, LLC [Member] | LOC Agreement [Member]  
Conversion of the $700,000 LOC with DKBK and related accrued interest on October 6, 2020 199,537